NCT02422641
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: Leptomeningeal Disease
Additional Notes: Patients must have evidence of leptomeningeal disease (LMD) with or without brain metastases
Exclusions: 
https://ClinicalTrials.gov/show/NCT02422641